Literature DB >> 17009112

The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy.

Lori A Coburn1, Paul E Wise, David A Schwartz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17009112     DOI： 10.1007/s10620-006-9452-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  12 in total

1.  Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody.

Authors:  G Treacy
Journal:  Hum Exp Toxicol       Date:  2000-04       Impact factor: 2.903

Review 2.  Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.

Authors:  R Rau
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

3.  Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries.

Authors:  K Fonager; H T Sørensen; J Olsen; J F Dahlerup; S N Rasmussen
Journal:  Am J Gastroenterol       Date:  1998-12       Impact factor: 10.864

4.  Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.

Authors:  M E Weinblatt; E C Keystone; D E Furst; A F Kavanaugh; E K Chartash; O G Segurado
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

5.  What next after infliximab?

Authors:  Leonard Baidoo; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

6.  Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.

Authors:  Konstantinos A Papadakis; Omid A Shaye; Eric A Vasiliauskas; Andrew Ippoliti; Marla C Dubinsky; Jaime Birt; Jane Paavola; Susie K Lee; Joanne Price; Stephan R Targan; Maria T Abreu
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

7.  Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.

Authors:  Jeffry A Katz; Christian Antoni; Gregory F Keenan; Deirdre E Smith; Stephen J Jacobs; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

8.  Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Authors:  Michael H Weisman; Larry W Moreland; Daniel E Furst; Michael E Weinblatt; Edward C Keystone; Harold E Paulus; Leah S Teoh; Raja B Velagapudi; Peter A Noertersheuser; G Richard Granneman; Steven A Fischkoff; Elliot K Chartash
Journal:  Clin Ther       Date:  2003-06       Impact factor: 3.393

9.  A pilot study of adalimumab in infliximab-allergic patients.

Authors:  Adrienne Youdim; Eric A Vasiliauskas; Stephan R Targan; Konstantinos A Papadakis; Andrew Ippoliti; Marla C Dubinsky; Juan Lechago; Jane Paavola; Jaime Loane; Susie K Lee; Joanne Gaiennie; Katie Smith; Jason Do; Maria T Abreu
Journal:  Inflamm Bowel Dis       Date:  2004-07       Impact factor: 5.325

10.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Authors:  Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2003-01
View more
  17 in total

Review 1.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

2.  Pregnancy in glycogen storage disease type Ib: gestational care and report of first successful deliveries.

Authors:  Aditi I Dagli; Philip J Lee; Catherine E Correia; Christina Rodriguez; Kaustav Bhattacharya; Linda Steinkrauss; Charles A Stanley; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2010-04-13       Impact factor: 4.982

Review 3.  Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.

Authors:  Ioannis Androulakis; Christos Zavos; Panagiotis Christopoulos; George Mastorakos; Maria Gazouli
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

4.  Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding.

Authors:  Harish Raja; Eric L Matteson; Clement J Michet; Justine R Smith; Jose S Pulido
Journal:  Transl Vis Sci Technol       Date:  2012-09-21       Impact factor: 3.283

5.  Adalimumab for the treatment of Crohn's disease.

Authors:  Andrea Cassinotti; Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Biologics       Date:  2008-12

6.  The use of anti-TNFα medications for rheumatologic disease in pregnancy.

Authors:  Megan Eb Clowse
Journal:  Int J Womens Health       Date:  2010-08-09

Review 7.  Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

Authors:  Renée M Marchioni; Gary R Lichtenstein
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

Review 8.  Inflammatory bowel diseases and management considerations: fertility and pregnancy.

Authors:  Maria Moscandrew; Sunanda Kane
Journal:  Curr Gastroenterol Rep       Date:  2009-10

9.  Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.

Authors:  Uma Mahadevan; Douglas C Wolf; Marla Dubinsky; Antoine Cortot; Scott D Lee; Corey A Siegel; Thomas Ullman; Sarah Glover; John F Valentine; David T Rubin; Jocelyn Miller; Maria T Abreu
Journal:  Clin Gastroenterol Hepatol       Date:  2012-11-28       Impact factor: 11.382

Review 10.  Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.

Authors:  Frank Hoentjen; Ad A van Bodegraven
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.